Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

GC Biopharma and Novelty Nobility sign an R&D agreement to develop therapies for geographic atrophy

GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeutics, for the joint research and development of a novel treatment for geographic atrophy...

BioCryst shares real-world data highlighting strong adherence and persistence with ORLADEYOยฎ (berotralstat)

BioCryst Pharmaceuticals, Inc. announced new real-world comparative research on the use of oral, once-daily ORLADEYOยฎ (berotralstat) that found high rates of adherence and persistence for ORLADEYO, similar to the rates observed with two other...

ARTHEx Biotech doses first patient in Phase I-IIa ArthemiRโ„ข trial for Myotonic Dystrophy Type 1

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced that the first participant has been dosed in the Randomized Placebo Controlled Double Blind...

Blue Earth Therapeutics shares positive Phase 1 results for Lutetium (177Lu) rhPSMA-10.1 Injection, advancing its clinical development

Blue Earth Therapeutics Ltd, an emerging leader in the development of therapeutic radiopharmaceuticals, today announced further positive developments for its novel investigational radioligand therapies. Enrolment of patients in the Phase 1 trial...

Doer Biologics announces the dosing of the first patient in a Phase 2 study of DR10624 for severe hypertriglyceridemia treatment.

Zhejiang Doer Biologics Co., Ltd. a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast...

Galmed releases Phase 3 Aramchol results in Hepatology.

Galmed Pharmaceuticals Ltd. a clinical-stage biopharmaceutical company for liver, metabolic and fibro-inflammatory diseases announced that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients...

EydisBio receives FDA Orphan Drug Designation for its TAK1 inhibitor to treat systemic sclerosis.

EydisBio, Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EYD-001, its highly selective and potent, orally bioavailable TAK1 inhibitor for the treatment of systemic sclerosis....

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

Anixa Biosciences, Inc. a biotechnology company focused on the treatment and prevention of cancer, announced its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by...

Aptar Pharma signs an exclusive agreement with Pulmotree to develop and promote the Kolibriโ„ข non-propellant liquid inhaler platform

Aptar Pharma, a global leader in drug delivery and active material science solutions and services, announced that it has entered into an exclusive collaboration agreement with PULMOTREE to lead the development and promotion of their Kolibriโ„ข...

AISA Pharma receives FDA orphan drug designation for AISA-021, a treatment for systemic sclerosis

Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AISA-021(cilnidipine), a fourth-generation calcium channel antagonist. Aisa is...

ProJenX announces the formation of its Clinical Advisory Board

ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, announced the...

China approves the Corina Intrauterine Drug-Eluting System as a novel treatment for moderate-to-severe intrauterine adhesions (IUA)

Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA) who...

ImmPACT Bio announces FDA clearance of its IND application for CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis

ImmPACT Bio USA Inc.a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients, announced the United States Food and Drug Administration (FDA)...

Gileadโ€™s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelziยฎ (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in...

Aptarโ€™s Nasal Unidose System will deliver neffyยฎ (epinephrine nasal spray), the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis

AptarGroup, Inc. a global leader in drug and consumer product dosing, dispensing and protection technologies, announced that its Unidose Liquid System (Unidose) is the delivery system approved with neffyยฎ (epinephrine nasal spray), the first and...

Citius Pharmaceuticals' LYMPHIRโ„ข wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

Citius Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LYMPHIRโ„ข (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma (CTCL) after at least one prior...

Clarivate introduces the new OFF-Xโ„ข platform for preclinical and clinical safety intelligence

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, announced the launch of the new OFF-Xโ„ข platform. The enhanced solution offers a seamless user experience and unique translational insights. It delivers crucial...

Galdermaโ€™s Relfydessโ„ข (RelabotulinumtoxinA) receives positive decision for use in Europe

Galderma announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for RelfydessTM (RelabotulinumtoxinA โ€“ previously referred to as QM1114). RelfydessTM is indicated for the temporary improvement...

Transposon announces Phase 2 results for TPN-101 in treating C9orf72-related ALS and frontotemporal dementia

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's disease, announced final results from its Phase...

Prolacta Bioscience Leads in Human Milk Science, Regularly Reviewing Health Claims with FDA

Prolacta Bioscienceยฎ, the world's leading hospital provider of 100% human milk-based nutritional products, takes its obligation to the critically ill and premature infants it serves, and to the doctors providing them with care, extremely...